Skip to main content
. 2016 Jun 1;9(6 Suppl 1):S7–S12.

Figure 3.

Figure 3

Efficacy through Week 52 in the FIXTURE study. This figure shows maintenance of response with regards to PASI 75, 90, and 100, and IGA 0 or 1 in secukinumab 300mg and150mg groups and etanercept group through Week 52.

Adapted from Langley et al. N Engl J Med. 2014;371(4):326-338.